| Product Name | CTXI ELISA kit (Mouse) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI). No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed. |
| Synonyms | CTX-I; CTX1; |
| Method | Competitive |
| Detection Range | 123.5-10,000pg/mL |
| Sensitivity | 44.7pg/mL |
| Target | CTXI |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI). No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed. |
| Reactivity | Mouse |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Atp6v0d2 Is an Essential Component of the Osteoclast-Specific Proton Pump That Mediates Extracellular Acidification in Bone Resorption;Borage and fish oils lifelong supplementation decreases inflammation and improves bone health in a murine model of senile osteoporosis;TRAF family member-associated NF-κB activator (TANK) is a negative regulator of osteoclastogenesis and bone formation;Oxytocin Reverses Ovariectomy-Induced Osteopenia and Body Fat Gain;XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa);5-azacytidine-induced protein 2 (AZI2) regulates bone mass by fine-tuning osteoclast survival;Mutation in Osteoactivin Promotes RANKL-Mediated Osteoclast Differentiation and Survival, but Inhibits Osteoclast Function;Oxytocin reverses osteoporosis in a sex-dependent manner;Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the DownreCavia (Guinea pig )lation of Rankl-Induced Nf-κb and Nfatc1 Activities;N-Homocysteinylation impairs collagen cross-linking in cystathionine β-synthase-deficient mice: a novel mechanism of connective tissue abnormalities.;Reduced femoral bone mass in both diet-induced and genetic hyperlipidemia mice;A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice.;Optimization of the Time Window of Interest in Ovariectomized Imprinting Control Region Mice for Antiosteoporosis Research;TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42;Combination therapy with BMP‑2 and psoralen enhances fracture healing in ovariectomized mice;Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling;Transcriptome analysis of osteoblasts in an ovariectomized mouse model in response to physical exercise;Significance of the Tks4 scaffold protein in bone tissue homeostasis;Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice;BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling;EDTA-Modified 17β-Estradiol-Laden Upconversion Nanocomposite for Bone-Targeted Hormone Replacement Therapy for Osteoporosis;RNA Sensing by Gut Piezo1 Is Essential for Systemic Serotonin Synthesis;A Loop‐Based and AGO‐Incorporated Virtual Screening Model Targeting AGO‐Mediated miRNA–mRNA Interactions for Drug Discovery to Rescue Bone Phenotype …;Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous …;4-Hexylresorcinol Inhibits Osteoclastogenesis by Suppressing NF‐κB Signaling Pathway and Reverses Bone Loss in Ovariectomized Mice;Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via the canonical Wnt/¦Â©\catenin pathway;Andrographolide prevents bone loss via targeting ERRalpha‐regulated metabolic adaption of osteoclastogenesis;Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression;BMP9 reduces age-related bone loss in mice by inhibiting osteoblast senescence through Smad1-Stat1-P21 axis;Foxf2 represses bone formation via Wnt2b/β-catenin signaling;Exercised accelerated the production of muscle-derived kynurenic acid in skeletal muscle and alleviated the postmenopausal osteoporosis through the Gpr35 …; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEA665Mu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
